Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Pharming Narrows 2026 Revenue Guidance to USD 380-390 Million

By Public Technologies
  • Pharming narrowed 2026 revenue guidance to US$ 380-390 million from US$ 375-395 million, implying 1-4% growth.
  • Operating expense guidance fell by US$ 5 million to US$ 310-315 million.
  • Third-quarter revenue rose 21% to US$ 117.6 million, supported by Joenja growth and RUCONEST’s return to growth.
  • The outlook assumes accelerating Joenja growth, with RUCONEST revenue stabilizing and returning to growth in the second half.
  • Available cash of US$ 190.9 million and future cash flows are expected to cover current pipeline and prelaunch costs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.